It's been 8 months in November since we were told:
"the U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD)"
..... and still no meeting (that we know of) ? Get on with it ... lol
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
0.065(3.62%) |
Mkt cap ! $2.376B | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.89 | $1.83 | $8.165M | 4.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6744 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 5904 | 3 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |